0001213900-17-010951.txt : 20171025
0001213900-17-010951.hdr.sgml : 20171025
20171025163537
ACCESSION NUMBER: 0001213900-17-010951
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171023
FILED AS OF DATE: 20171025
DATE AS OF CHANGE: 20171025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sank Leonard
CENTRAL INDEX KEY: 0001416089
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35813
FILM NUMBER: 171153381
MAIL ADDRESS:
STREET 1: 3 BLAIR ROAD
CITY: CAPE TOWN
STATE: T3
ZIP: 8005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ORAMED PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0001176309
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980376008
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0831
BUSINESS ADDRESS:
STREET 1: HI-TECH PARK 2/4 GIVAT-RAM
STREET 2: PO BOX 39098
CITY: JERUSALEM
STATE: L3
ZIP: 91390
BUSINESS PHONE: 011 972-2-566-0001
MAIL ADDRESS:
STREET 1: HI-TECH PARK 2/4 GIVAT-RAM
STREET 2: PO BOX 39098
CITY: JERUSALEM
STATE: L3
ZIP: 91390
FORMER COMPANY:
FORMER CONFORMED NAME: Integrated Security Technologies, Inc.
DATE OF NAME CHANGE: 20040614
FORMER COMPANY:
FORMER CONFORMED NAME: IGUANA VENTURES LTD
DATE OF NAME CHANGE: 20020625
4
1
f4102317sank_oramedpharm.xml
OWNERSHIP DOCUMENT
X0306
4
2017-10-23
0
0001176309
ORAMED PHARMACEUTICALS INC.
ORMP
0001416089
Sank Leonard
3 BLAIR ROAD
CAPE TOWN
T3
8005
SOUTH AFRICA
1
0
0
0
Common Stock
2017-10-23
4
M
0
5631
6.00
A
287789
D
Common Stock
2017-10-23
4
M
0
6373
6.00
A
294162
D
Common Stock
78125
I
Via spouse
Common Stock
138889
I
Via trust
Warrant (right to buy)
6.00
2017-10-23
4
M
0
5631
1.1796
D
2012-11-02
2017-11-02
Common Stock
5631
0
D
Warrant (right to buy)
6.00
2017-10-23
4
M
0
6373
D
2013-02-07
2018-02-07
Common Stock
6373
0
D
Mr. Sank disclaims beneficial ownership of these shares.
These shares consist of shares of common stock owned by a company wholly owned by a trust of which Mr. Sank is a trustee. Mr. Sank disclaims beneficial ownership of these shares.
The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.
The shares of common stock and warrants were granted to Mr. Sank as a finder's fee in connection with a 2012 private placement of the Issuer.
/s/ Leonard Sank
2017-10-25